| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President &CEO | Director
2 companies
Raab Michael is a President &CEO at ARDX, with reported holdings spanning 2 companies. Recent filings cover 1 purchase and 75 sales. Those positions are worth an estimated $7.0M at current prices.
Our model assigns Raab Michael a middling insider score of 56/100, based on 47 past trades. Over a 12-month horizon, 46.7% of those trades were profitable, with an average 12-month return of -10.7%.
Raab Michael's largest disclosed position is in ARDX as President &CEO, worth about $7.0M. The recent filings there lean toward selling, a net 1,269,978 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 16, 2018 | FOLD Amicus Therapeutics, Inc. | Director | Sale+OE | 5,000 | $14.41 | $72,057.50 | -46.2% | |
| Jan 2, 2018 | FOLD Amicus Therapeutics, Inc. | Director | Sale+OE | 9,366 | $15.00 | $140,490.00 | -61.7% | |
| Oct 12, 2017 | FOLD Amicus Therapeutics, Inc. | Director | Sale+OE | 10,000 | $14.25 | $142,534.00 | -63.2% | |
| Sep 8, 2015 | ARDX Ardelyx, Inc. | President &CEO | Sell | 9,785 | $20.29 | $198,544.50 | -12.2% | |
| Aug 18, 2015 | ARDX Ardelyx, Inc. | President &CEO | Sell | 1,104 | $20.00 | $22,080.00 | -1.4% | |
| Aug 3, 2015 | ARDX Ardelyx, Inc. | President &CEO | Sell | 300 | $20.00 | $6,000.00 | -0.4% | |
| Jul 28, 2015 | ARDX Ardelyx, Inc. | President &CEO | Sell | 2,111 | $20.00 | $42,220.00 | -2.5% |